Ataxia Telangiectasia (AT) is a rare incurable genetic disease, caused by biallelic mutations in the Ataxia Telangiectasia-Mutated (ATM) gene. Treatment with glucocorticoid analogues has been shown to improve the neurological symptoms that characterize this syndrome. Nevertheless, the molecular mechanism underlying the glucocorticoid action in AT patients is not yet understood. Recently, we have demonstrated that Dexamethasone treatment may partly restore ATM activity in AT lymphoblastoid cells by a new ATM transcript, namely ATMdexa1.
ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T
MENOTTA, MICHELE;BIAGIOTTI, SARA;SPAPPERI, CHIARA;ORAZI, SARA;ROSSI, LUIGIA;MAGNANI, MAURO
2017
Abstract
Ataxia Telangiectasia (AT) is a rare incurable genetic disease, caused by biallelic mutations in the Ataxia Telangiectasia-Mutated (ATM) gene. Treatment with glucocorticoid analogues has been shown to improve the neurological symptoms that characterize this syndrome. Nevertheless, the molecular mechanism underlying the glucocorticoid action in AT patients is not yet understood. Recently, we have demonstrated that Dexamethasone treatment may partly restore ATM activity in AT lymphoblastoid cells by a new ATM transcript, namely ATMdexa1.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Menotta_et_al-2017-Orphanet_Journal_of_Rare_Diseases.pdf
accesso aperto
Tipologia:
Versione editoriale
Licenza:
Creative commons
Dimensione
1.34 MB
Formato
Adobe PDF
|
1.34 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
